Zobrazeno 1 - 10
of 164
pro vyhledávání: '"William B. Mattes"'
Autor:
Ian Kimber
Publikováno v:
ChemMedChem. 4:292-292
Autor:
William B. Mattes
Publikováno v:
Current Opinion in Toxicology. :114-118
The science of in vitro studies has advanced dramatically over the last 100 years, particularly in regards to their application in toxicology. Recent developments such as in vitro three-dimensional cultures and microphysiological systems have offered
Publikováno v:
Archives of Toxicology. 94:1215-1227
Addiction is a complex behavioral phenomenon in which naturally occurring or synthetic chemicals modulate the response of the reward system through their binding to a variety of neuroreceptors, resulting in compulsive substance-seeking and use despit
Autor:
William B. Mattes, Michael A. Schmidt, Julian C Schmidt, Richard D. Beger, Dean P. Jones, Bonnie V. Dougherty
Publikováno v:
Int J Toxicol
Metabolomics is unique among omics technologies in being applicable to metabolism and toxicity studies broadly across organisms (e.g., humans, other mammals, model organisms, and even bacteria) and across biological materials (e.g., blood, urine, sal
Autor:
Dan A Buzatu, Ted J Moskal, Anna J Williams, Willie Mae Cooper, William B Mattes, Jon G Wilkes
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e94254 (2014)
Foodborne illnesses occur in both industrialized and developing countries, and may be increasing due to rapidly evolving food production practices. Yet some primary tools used to assess food safety are decades, if not centuries, old. To improve the t
Externí odkaz:
https://doaj.org/article/68c5deea9df044c7bfbf09e732b0733c
Autor:
Daniel M. Gatti, Gary Larson, Alison H. Harrill, William B. Mattes, Lascelles E. Lyn-Cook, Dahea You, Philip R. Mayeux, Natalie Bell, Laura P. James
Publikováno v:
Toxicol Sci
Zileuton is an orally active inhibitor of leukotriene synthesis for maintenance treatment of asthma, for which clinical usage has been associated with idiosyncratic liver injury. Mechanistic understanding of zileuton toxicity is hampered by the rarit
Publikováno v:
Expert opinion on drug metabolismtoxicology. 16(3)
Introduction: As of October 2019, the U.S. Food and Drug Administration (FDA) has approved 53 small molecule kinase inhibitors (KI), which account for about 10% of all FDA-approved new molecular en...
Autor:
Xi Yang, Thomas Papoian, Matthew White, Qiangen Wu, James Greenhaw, Tashika Harris, Lijun Ren, Jun Zhang, Matthew Bryant, Qiang Shi, William B. Mattes
Publikováno v:
Toxicology Letters. 291:138-148
Of the 34 FDA approved oral small-molecule kinase inhibitors (KI), 23 (68%) have warnings for hepatotoxicity in product labeling. To better understand the mechanisms of KI hepatotoxicity and whether such effects can be predicted, we examined 34 KIs f
Autor:
Kostiantyn Dreval, William B. Mattes, Yongli Guo, Linjuan Zeng, Yaqiong Jin, Weida Tong, Huixiao Hong, Sudeepa Bhattacharyya, Hong Fang, Bridgett Knox, Tieliu Shi, Leming Shi, Yong Wang, Wenming Xiao, Zhen Ren, Igor P. Pogribny, Leihong Wu, Volodymyr Tryndyak, Jinchun Sun, Si Chen, Baitang Ning, Pritmohinder S. Gill, Richard D. Beger, Yinting Chen, Xi Yang, William H. Tolleson, Sandra S. McCullough, Laura K. Schnackenberg, Lei Guo, Nan Mei, Dianke Yu, Laura P. James
Publikováno v:
Archives of Toxicology. 92:845-858
Acetaminophen (APAP) overdose is the leading cause of acute liver failure. Yet the mechanisms underlying adaptive tolerance toward APAP-induced liver injury are not fully understood. To better understand molecular mechanisms contributing to adaptive
Publikováno v:
Current Opinion in Toxicology. 4:59-65
While biomarker discovery is receiving increased attention in both drug and chemical safety assessment, a critical step is transitioning a biomarker from an experimental observation to a useful assay is that of analytical validation. This is particul